Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55902, USA.
Mayo Clinic Library, Mayo Clinic, Rochester, MN, USA.
J Cardiothorac Surg. 2021 May 31;16(1):157. doi: 10.1186/s13019-021-01549-0.
Lidocaine is one of the most widely used local anesthetics with well-known pharmacological properties. The purpose of this systematic review is to investigate the effects of lidocaine on postoperative pain scores and recovery after cardiac surgery.
A comprehensive database search was conducted by a reference librarian for randomized clinical trials (RCT) from January 1, 1980 to September 1, 2019. Eligible study designs included randomized controlled trials of lidocaine for postoperative pain management in adults undergoing cardiac surgery. After removal of duplicates, 947 records were screened for eligibility and 3 RCTs met inclusion criteria.
Sources of bias were identified in 2 of 3 RCTs. Lidocaine was administered intravenously, topically, and intrapleurally. Key findings included [1] 2% lidocaine placed topically on chest tube prior to intraoperative insertion was associated with significantly lower pain scores and lower cumulative doses of fentanyl; and [2] 2% lidocaine administered intrapleurally was associated with significantly lower pain scores and significant improvements in pulmonary mechanics. Lidocaine infusions were not associated with significant changes in pain scores or measures of recovery. No significant associations were observed between lidocaine and overall mortality, hospital length of stay or ICU length of stay. No data were reported for postoperative nausea and vomiting or arrhythmias.
Due to the favorable risk profile of topical lidocaine and the need for further advancements in the postoperative care of adults after cardiac surgery, topically administered lidocaine could be considered for incorporation into established postoperative recovery protocols.
利多卡因是最广泛使用的局部麻醉剂之一,具有众所周知的药理学特性。本系统评价的目的是调查利多卡因对心脏手术后疼痛评分和恢复的影响。
由参考馆员进行全面的数据库搜索,以查找 1980 年 1 月 1 日至 2019 年 9 月 1 日的随机临床试验(RCT)。合格的研究设计包括利多卡因用于接受心脏手术的成年人术后疼痛管理的随机对照试验。去除重复项后,筛选了 947 份记录以确定其是否符合入选标准,其中 3 项 RCT 符合入选标准。
3 项 RCT 中有 2 项确定存在偏倚来源。利多卡因静脉内、局部和胸膜内给药。主要发现包括:[1]在术中插入前将 2%利多卡因局部涂于胸管上,疼痛评分和芬太尼累积剂量明显降低;[2]胸膜内给予 2%利多卡因,疼痛评分明显降低,肺力学显著改善。利多卡因输注与疼痛评分或恢复测量无显著变化。利多卡因与死亡率、住院时间或 ICU 住院时间之间未观察到显著关联。未报告术后恶心和呕吐或心律失常的数据。
由于局部利多卡因的良好风险状况以及需要进一步改进心脏手术后成年人的术后护理,因此可以考虑将局部给予的利多卡因纳入既定的术后恢复方案中。